Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GH) have received a consensus rating of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and fourteen have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $37.38.

Several research firms have commented on GH. Craig Hallum started coverage on shares of Guardant Health in a research note on Wednesday, April 24th. They issued a “buy” rating and a $28.00 target price for the company. Stephens reiterated an “overweight” rating and set a $44.00 target price on shares of Guardant Health in a research report on Friday, May 24th. Bank of America raised their price target on Guardant Health from $28.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 18th. Guggenheim raised shares of Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 price objective for the company in a research note on Friday, June 28th. Finally, Jefferies Financial Group began coverage on shares of Guardant Health in a research report on Monday, June 3rd. They issued a “buy” rating and a $32.00 target price on the stock.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $32.68 on Friday. Guardant Health has a 12 month low of $15.81 and a 12 month high of $41.06. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of -8.34 and a beta of 1.13. The business’s 50 day simple moving average is $28.67 and its 200-day simple moving average is $23.27. The company has a debt-to-equity ratio of 16.70, a current ratio of 5.95 and a quick ratio of 5.66.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, May 9th. The company reported ($0.94) earnings per share for the quarter, meeting the consensus estimate of ($0.94). The company had revenue of $168.49 million for the quarter, compared to analyst estimates of $150.51 million. Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. As a group, equities analysts forecast that Guardant Health will post -3.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

A number of large investors have recently modified their holdings of GH. Manchester Capital Management LLC acquired a new stake in Guardant Health during the 1st quarter valued at $57,000. Canton Hathaway LLC acquired a new stake in shares of Guardant Health during the second quarter valued at about $59,000. Headlands Technologies LLC increased its position in shares of Guardant Health by 362.3% during the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after acquiring an additional 1,844 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Guardant Health by 29.4% during the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock worth $73,000 after acquiring an additional 614 shares during the last quarter. Finally, EntryPoint Capital LLC acquired a new position in shares of Guardant Health in the first quarter worth about $75,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.